LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Search

Arcutis Biotherapeutics Inc

Затворен

СекторЗдравеопазване

20.39 4.67

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

19.54

Максимум

20.7

Ключови измерители

By Trading Economics

Приходи

-29M

-11M

Продажби

-24M

105M

EPS

-0.09

Марж на печалбата

-10.717

Служители

354

EBITDA

-31M

-8.5M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+77.59% upside

Дивиденти

By Dow Jones

Следващи печалби

5.08.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-433M

2.5B

Предишно отваряне

15.72

Предишно затваряне

20.39

Настроения в новините

By Acuity

50%

50%

159 / 345 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Arcutis Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.05.2026 г., 23:31 ч. UTC

Горещи акции

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20.05.2026 г., 22:52 ч. UTC

Значими двигатели на пазара

Osisko Shares Fall on Planned Convertible Notes Offering

20.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

20.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20.05.2026 г., 23:44 ч. UTC

Печалби

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20.05.2026 г., 23:35 ч. UTC

Пазарно говорене

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20.05.2026 г., 23:30 ч. UTC

Пазарно говорене

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20.05.2026 г., 23:17 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

20.05.2026 г., 23:17 ч. UTC

Пазарно говорене

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20.05.2026 г., 23:15 ч. UTC

Пазарно говорене

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20.05.2026 г., 23:14 ч. UTC

Печалби

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20.05.2026 г., 23:02 ч. UTC

Пазарно говорене

KMD Brands Faces Two Testing Hurdles -- Market Talk

20.05.2026 г., 22:57 ч. UTC

Пазарно говорене

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20.05.2026 г., 22:57 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

20.05.2026 г., 22:57 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

20.05.2026 г., 22:51 ч. UTC

Пазарно говорене

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20.05.2026 г., 22:51 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

20.05.2026 г., 22:27 ч. UTC

Пазарно говорене

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20.05.2026 г., 22:14 ч. UTC

Пазарно говорене

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20.05.2026 г., 22:10 ч. UTC

Печалби

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20.05.2026 г., 22:00 ч. UTC

Печалби

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20.05.2026 г., 21:38 ч. UTC

Печалби
Придобивния, сливания и поглъщания

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20.05.2026 г., 21:27 ч. UTC

Печалби

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20.05.2026 г., 21:20 ч. UTC

Печалби

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20.05.2026 г., 21:19 ч. UTC

Печалби

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20.05.2026 г., 21:18 ч. UTC

Печалби

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20.05.2026 г., 21:17 ч. UTC

Печалби

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20.05.2026 г., 21:17 ч. UTC

Печалби

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20.05.2026 г., 21:17 ч. UTC

Печалби

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20.05.2026 г., 21:16 ч. UTC

Печалби

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Arcutis Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

77.59% нагоре

12-месечна прогноза

Среден 34.63 USD  77.59%

Висок 36 USD

Нисък 33 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Arcutis Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

7

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

12.42 / 14.93Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

159 / 345 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
help-icon Live chat